Recursion Pharmaceuticals Inc
- 거래소
- 미국
- 국가 / 지역
- USA
- 상장일
- 2021년 4월 16일
- 직원 수
- 600
종합 밸류에이션 구간 · 보수적 $1.5–$2.8 / 적정 $3–$5 / 낙관적 $7–$10. $3.23 기준, 적정 내재가치 구간 내.
보고서 발행 시 $3.32（2026년 6월 8일）
이 종목에 대한 리포트가 아직 해당 언어로 없습니다.
Recursion Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery in the United States and the United Kingdom. The company develops REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-617, which is in Phase 1/2 clinical trial to treat advanced solid tumors; REC-1245, which is in Phase 1/2 clinical trial to treat biomarker-enriched solid tumors and lymphoma; REC-3565 that is in Phase 1/2 for the treatment of relapsed or refractory B-cell malignancies; and REC-4539, a reversible, CNS penetrant, orally bioavailable, and potential best-in-class inhibitor of LSD1 for the treatment of solid tumors and hematology oncology. Its preclinical stage product includes REC-7735 for the treatment of HR+ breast cancer; and REC-102 for the treatment of hypophosphatasia. The company has collaboration and agreement with Roche & Genentech; Sanofi; Bayer AG; Tempus; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
데이터 제공: EODHD, 보고 통화 기준 표시. 참고용일 뿐 투자 자문이 아닙니다.
연혁
준비 중이 섹션은 작성 중입니다. 곧 다시 확인해 주세요.
업계 내 위치
준비 중이 섹션은 작성 중입니다. 곧 다시 확인해 주세요.